Overview

A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06427878 in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer